Laboratorios Richmond SACIF Total Liabilities
Laboratorios Richmond SACIF total liabilities. Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) has total liabilities worth AR$282.24 Billion ARS (≈ $204.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Laboratorios Richmond SACIF liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Laboratorios Richmond SACIF (2006–2024)
Total liabilities of Laboratorios Richmond SACIF from 2006 to 2024. This chart illustrates how Laboratorios Richmond SACIF's total liabilities have evolved over time, based on quarterly financial data. Explore Laboratorios Richmond SACIF strategic investment ratio to see how much of total assets are deployed in long-term investments.
Laboratorios Richmond SACIF Competitors by Total Liabilities
The table below lists competitors of Laboratorios Richmond SACIF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TEKNA HOLDING ASA NK 2
F:8VB
|
Germany | €18.33 Million |
|
DCC plc
LSE:DCC
|
UK | GBX5.52 Billion |
|
Deneb Investments Ltd
JSE:DNB
|
South Africa | ZAC1.34 Billion |
|
Hai Kwang Enterprise Corp
TW:2038
|
Taiwan | NT$5.04 Billion |
|
Internet Thailand Public Company Limited
BK:INET
|
Thailand | ฿13.99 Billion |
|
LENSAR Inc
NASDAQ:LNSR
|
USA | $54.65 Million |
|
Lion Finance Group PLC
LSE:BGEO
|
UK | GBX56.43 Billion |
|
Tycoons Group Enterprise Co Ltd
TW:2022
|
Taiwan | NT$4.50 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Laboratorios Richmond SACIF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Laboratorios Richmond SACIF balance sheet assets.
Liquidity & Leverage Metrics
Laboratorios Richmond SACIF Total Liabilities Ratios Explained
Laboratorios Richmond SACIF total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laboratorios Richmond SACIF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual total liabilities of Laboratorios Richmond SACIF from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AR$194.80 Billion ≈ $140.96 Million |
-32.20% |
| 2023-12-31 | AR$287.34 Billion ≈ $207.92 Million |
+842.02% |
| 2022-12-31 | AR$30.50 Billion ≈ $22.07 Million |
+50.13% |
| 2021-12-31 | AR$20.32 Billion ≈ $14.70 Million |
+327.48% |
| 2020-12-31 | AR$4.75 Billion ≈ $3.44 Million |
+56.62% |
| 2019-12-31 | AR$3.03 Billion ≈ $2.20 Million |
+90.35% |
| 2018-12-31 | AR$1.59 Billion ≈ $1.15 Million |
+84.39% |
| 2017-12-31 | AR$864.59 Million ≈ $625.62K |
+28.72% |
| 2016-12-31 | AR$671.67 Million ≈ $486.03K |
+53.80% |
| 2015-12-31 | AR$436.71 Million ≈ $316.01K |
+49.23% |
| 2014-12-31 | AR$292.64 Million ≈ $211.76K |
+49.05% |
| 2013-12-31 | AR$196.34 Million ≈ $142.07K |
+9.72% |
| 2012-12-31 | AR$178.94 Million ≈ $129.48K |
+64.29% |
| 2011-12-31 | AR$108.92 Million ≈ $78.82K |
+19.74% |
| 2010-12-31 | AR$90.96 Million ≈ $65.82K |
+22.74% |
| 2009-12-31 | AR$74.11 Million ≈ $53.62K |
+3.88% |
| 2008-12-31 | AR$71.34 Million ≈ $51.62K |
+10.89% |
| 2007-12-31 | AR$64.33 Million ≈ $46.55K |
+32.35% |
| 2006-12-31 | AR$48.61 Million ≈ $35.17K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more